Article Per Year (5 Year)
p-Index From 2021 - 2026
2.723
P-Index
This Author published in this journals
All Journal The Indonesian Biomedical Journal Indonesian Journal of Obstetrics and Gynecology (Majalah Obstetri dan Ginekologi Indonesia) Jurnal Ilmiah Kesehatan Jurnal Ilmiah Kebidanan Indonesia (Indonesian Midwifery Scientific Journal) Journal of the Indonesian Medical Association : Majalah Kedokteran Indonesia Andalas obstetrics and gynecology journal Medika Teknika : Jurnal Teknik Elektromedik Indonesia Cermin Dunia Kedokteran Jurnal Ilmu Kesehatan Indonesia (JIKSI) Makara Journal of Health Research Cermin Dunia Kedokteran
Hariyono Winarto
Department Of Obstetrics And Gynecology, Faculty Of Medicine, Universitas Indonesia - Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia
Biochemistry, Genetics & Molecular Biology Education Electrical & Electronics Engineering Health Professions Immunology & microbiology Medicine & Pharmacology Nursing Public Health

Published : 33 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 33 Documents
Search

 1   2   3   4 
Eliminating Cervical Cancer in Asia–Pacific: From HPV Policy to Real-World Oncology Practice Hariyono Winarto
Indonesian Journal of Obstetrics and Gynecology Volume 14. No. 1 January 2026
Publisher : Indonesian Socety of Obstetrics and Gynecology

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32771/inajog.v14i1.3200

Abstract

Cervical cancer remains a major burden in Asia-Pacific, with nearly 70% of women presenting at advanced stages and survival rates for metastatic disease as low as 17.6%. Despite WHO’s 90-70-90 targets for 2030, vaccination and screening coverage remain insufficient, and treatment capacity—especially brachytherapy—faces severe shortages, with a deficit of 904 machines in the region. Recent progress, such as school-based HPV vaccination programs and evidence supporting single-dose efficacy, offers hope, but prevention must be tightly linked with screening and timely treatment. Oncologists are urged to integrate vaccination histories into clinical records, promote HPV testing and self-sampling, and ensure guideline-concordant chemoradiation. Robust local data on stage distribution and treatment completion are essential to drive policy and funding. Ultimately, aligning HPV policy with oncology practice is critical to transform elimination from aspiration into reality within professional lifetimes.
Pendekatan Konservatif pada Kanker Serviks Selama Kehamilan Rima Irwinda; Lisa Novianti; M Adya F Dilmy; Hariyono Winarto
Andalas Obstetrics And Gynecology Journal Vol. 10 No. 2 (2026)
Publisher : Fakultas Kedokteran Universitas Andalas

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.25077/aoj.10.2.194-217.2026

Abstract

Background: Cervical cancer diagnosed during pregnancy poses a complex clinical and ethical dilemma, requiring a balance between timely maternal cancer treatment and fetal preservation. Recent studies show that pregnancy itself does not worsen long-term cancer outcomes, allowing for a more individualized approach especially in early-stage disease, where delaying treatment until fetal viability can be both safe and practical   Purpose: This evidence-based review aimed to summarize current evidence on the safety and outcomes of conservative management for early-stage cervical cancer during pregnancy   Methods: We explored journal databases (PubMed, Cochrane, and Google Scholar). We included meta-analyses, systematic reviews, or observational studies published in English   Results: We found three studies that fulfilled our inclusion criteria; they were two meta-analyses and one retrospective cohort study. Zuoxi et al concluded that there was no survival difference between the 2 groups (100% vs. 90.91%, P=0.54), and none of the pregnant women who died had delayed treatment due to pregnancy. Zeng et al, the primary outcome of interest is long-term survival, as pregnancy termination and timing of delivery did not significantly affect the 5-year OS (P > 0.05).   Conclusion: This evidence-based case report underscores the feasibility and clinical efficacy of a conservative, individualized management strategy for patients diagnosed with early-stage cervical cancer during pregnancy, where a comprehensive understanding of current evidence empowers clinicians and patients to collaborate on treatment plan that addresses both maternal survival and fetal well-being.
Gambaran Myelosupresi pada pasien Kanker Ovarium yang Menerima Kemoterapi Carboplatin-Paclitaxel di RSUPN Cipto Mangunkusumo Tahun 2018 Hariyono Winarto; Andrew Wijaya
Majalah Kedokteran Indonesia Vol 70 No 4 (2020): Journal of The Indonesian Medical Association - Majalah Kedokteran Indonesia, Vo
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47830/jinma-vol.70.4-2020-160

Abstract

Background: Ovarian cancer has the highest mortality rate among other gynecologic cancers with poor prognosis due to unspecific symptoms. Ovarian cancer is mainly treated by surgical and chemotherapy combination. Despite its curative effect chemotherapy’s, myelosuppressive is a notable side effect and may impact the next cycle of chemotherapy. This study is aimed to record laboratory changes in chemotherapy recipient in Cipto Mangunkusumo Hospital.Methods: Hemoglobin, Absolute Neutrophil Count (ANC), and thrombocyte data are obtained from medical records whose received 6 cycles of Carboplatin-Paclitaxel from January-December 2018. Patients who received other chemotherapy and bone marrow metastasis were excluded.Results: Sixteen patients who completed 6 cycles were recorded. Baseline hemoglobin was 11.30±0.887 mg/dL and mean reduction was 0.29 g/dL per cycle. Mean ANC was 5,394.43±2096 cells/mm3, mean reduction was 543 cells/mm3 per cycle, and 5,35% developed neutropenia. Mean thrombocyte level was 34.225 cells/mm3 and 23% developed thrombocytopenia.Conclusions: Carboplatin-Paclitaxel’s effect on myelosuppression is prominent within the first cycle. Extra precaution must be done to prevent unwanted events.
Co-Authors Abdullah, Muhammad Raoul Taufiq Addin Trirahmanto Adiyarianni, Ghina Aldri Frinaldi Alexander AW Peters Amalia, Gassani Andi Darma Putra Andrew Wijaya Andrijono Andrijono Andrijono Andrijono Andrijono Anggaraeni, Tricia Dewi Ani Retno Prijanti Antonius, Puja Agung Aria Kekalih Bambang Sutrisna Bambang Sutrisna Bambang Sutrisna Bambang Sutrisna Bambang Sutrisna Binathara, Geraldus Sigap Gung Bismarck J. Laihad Budiningsih Siregar Budiningsih Siregar Calvin, David Daud, Sulaeman Dhanasari Vidiawati Ediwibowo Ambari Ediwibowo Ambari Eka R Gunardi Erwin Rahakbauw Faisha Rahma, Melly Fauzi Ahmad Muda Ferry Sandra Fitriyadi Kusuma Gatot Purwoto Heru Prasetyo Indra, Ken Jamhari Jamhari Kartiwa H Nuryanto Kartiwa Hadi Nuryanto Kemal Akbar Suryoadji Ken Indra Laila Nuranna Lisa Novianti M Adya F Dilmy Madjid, Veinardi Malano, Yoarva Markus, Unedo H Markus, Unedo H Maulana, Muhammad Sobri Michael Adrian Muhammad Haekal Muhammad Haekal Nana Supriana Nana Supriana Nuryanto, Kartiwa H Putra, Abdul Hafiidh Surya Rahakbauw, Erwin Ratnasari, Affi Angelia Ridwan, Alifaturrasyid Syafaatullah Rima Irwinda Rizky Humairah , Inas Sigit Purbadi Sini, Kieran Pasha Ivan Soloan, Garry Sri M. Sekarutami Sulaeman Daud Suryoadji, Kemal Akbar Tiara Aninditha Tofan Widya Utami Tofan Widya Utami Tricia Dewi Anggraeni Unedo H Markus Utami, Tofan Widya Widya Utami, Tofan William Halim Wulandari, Anisa Saphira